Company intelligence / Profile preview
Pharmosa Biopharm Inc.
Taipei, Taipei City, Taiwanpharmosa.com.tw ↗
- Ownership
- Public · 6875
- Development stage
- Phase 3
01
Overview
Pharmosa Biopharm is developing innovative drug-device combinations, notably L606 for PAH and PH-ILD, using its proprietary liposomal formulation.
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- Small moleculesLiposomal formulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MenagenLiquidia Corporation
Beyond the preview
Go deeper on Pharmosa Biopharm Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmosa Biopharm Inc..